Sept. 14 (UPI) -- A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer cells, which is called cachexia, Pfizer said in a news release Saturday. Advertisement "Cachexia is a common condition in cancer patients associated with weight loss, functional decline and,

Tag-uri: Pfizer